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Abstract
Reliable detection of large deletions from cell-free fetal DNA (cffDNA) in maternal plasma is challenging, especially when
both parents have the same deletion owing to a lack of specific markers for fetal genotyping. In order to evaluate the
efficacy of a non-invasive prenatal diagnosis (NIPD) test to exclude a-thalassemia major that uses SNPs linked to the normal
paternal a-globin allele, we established a novel protocol to reliably detect paternal SNPs within the (22
SEA) breakpoints
and performed evaluation of the diagnostic potential of the protocol in a total of 67 pregnancies, in whom plasma samples
were collected prior to invasive obstetrics procedures in southern China. A group of nine SNPs identified within the deletion
breakpoints were scanned to select the informative SNPs in each of the 67 couples DNA by multiplex PCR based mini-
sequencing technique. The paternally inherited SNP allele from cffDNA was detected by allele specific real-time PCR. A
protocol for reliable detection of paternal SNPs within the (22
SEA) breakpoints was established and evaluation of the
diagnostic potential of the protocol was performed in a total of 67 pregnancies. In 97% of the couples one or more different
SNPs within the deletion breakpoint occurred between paternal and maternal alleles. Homozygosity for the (22
SEA)
deletion was accurately excluded in 33 out of 67 (49.3%, 95% CI, 25.4–78.6%) pregnancies through the implementation of
the protocol. Protocol was completely concordant with the traditional reference methods, except for two cases that
exhibited uncertain results due to sample hemolysis. This method could be used as a routine NIPD test to exclude gross
fetal deletions in a-thalassemia major, and could further be employed to test for other diseases due to gene deletion.
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Introduction
a-Thalassaemia is the most common monogenic inheritance
disorder in tropical and subtropical areas in the world with a carrier
frequency reaching as high as 10–15% in Southeast Asia, the Indian
subcontinent, and Southern China [1],[2]. This inherited anemia
syndrome mainly results from gross deletions of the human a-globin
gene cluster mapped to chromosome 16p13.3, and thus is char-
acterized by a reduction or complete suppression of a-globin chain
synthesis [1],[3]. Deletion of the double a-globin gene is designated
as a
0-thalassaemia, such as 22
SEA, 22
FIL and22
THAI, which is
more prevalent in southeastern Asia including southern China. This
deletion can result in a fatal condition, hemoglobin (Hb) Bart’s
hydrops fetalis, when the deletion is homozygous [4]. When both
parents are a
0-thalassaemia carriers, each pregnancy has a 25% risk
for Hb Bart’s hydrops. An affected fetus can be effectively detected
by prenatal diagnosis for at-risk couples by fetal sampling via
amniocentesis and chorionic villus sampling (CVS). However, such
traditional techniques are invasive and carry a small but significant
risk of miscarriages (0.5–1%) [5].
Fetal nucleated red blood cells [6]–[9], or cell-free fetal DNA
(cffDNA) [10]–[13], that exist in maternal circulation during
pregnancy offers a potential source of fetal material for non-invasive
prenatal diagnosis (NIPD) of the fetal genetic status. Reliable NIPD
tests using cffDNA has recently been used to detect paternally
inherited genetic traits, such as Y-linked disorders and rhesus D
[13]. A panel of highly sensitive technologies to detect paternally
inherited fetal point mutations [14], has been developed and NIPD
using cffDNA has been applied to a group of single gene disorders
including b-thalassemia [15]–[18], cystic fibrosis [19], and congen-
ital adrenal hyperplasia (CAH) [20], and has been used on the
targeted genes in couples who carry different mutations in
particular. It has been demonstrated that an alternative approach
for detection of different SNPs linked to the mutant allele in parents
with identical point mutations is potentially useful in non-invasive
diagnosis using cffDNA [21].
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from cffDNA in maternal plasma when couples share the same
deletion due to the lack of specific markers for fetal genotyping. In
addition, the fragmented nature of cffDNA is not conducive to
efficient detection of large deletions using a PCR-based technique
[22]. Recently, Ho et al. reported a method for identification of
non-deleted paternally inherited fetal alleles in cell-free DNA
(cfDNA) using two microsatellite markers within deletion break-
points in NIPD for Hb Bart’s syndrome [22], [23]. The number of
polymorphic STRs in the region of interest is a disadvantage as it
is limited, and therefore the method is only applicable for one-
third of pregnancies [23]. Using a-thalassaemia as a diagnostic
target, we present a novel strategy for the noninvasive prenatal
diagnosis of a homozygous deletion using multiplex SNP dis-
crimination of fetal DNA from maternal plasma. In this study we
established a protocol for the reliable detection of a panel of
paternal SNPs within the (22
SEA) breakpoints in cfDNA samples
and evaluated 67 pregnancies at risk for a-thalassemia major;
moreover, we demonstrated the feasibility and reliability of this
NIPD method.
Materials and Methods
Sample collection
A total of 150 normal unrelated individuals and 150 aa/22
SEA
carriers were recruited for characterization of SNPs within the
(22
SEA) breakpoints in the a-globin gene cluster (Accession
NG_000006.1).To establish multiplex PCR-based mini-sequenc-
ing for simultaneous scanning of multiple SNPs, 40 standard
sequenced samples were used in the study. 10 mL maternal blood
samples were collected into two 5 mL EDTA blood collection
tubes. Maternal plasma samples from 67 pregnant women at risk
for a-thalassemia major were collected prior to invasive obstetrics
procedures (8.5–25 weeks of gestation, mean 19.12 weeks, before
chorionic villus sampling in the first trimester and before
amniocentesis in the second trimester) between June 2008 and
June 2010 in southern China. The patients’ age ranged from 20 to
41 years with a mean of 27 years and median of 26 years. Both of
the parents of each pregnancy carried an identical (22
SEA)
deletion except for one case. The study was approved by the
Ethics Committee of Nanfang Hospital, an affiliate of Southern
Medical University, China. Detailed written informed consent was
obtained from all participants.
Blood processing and maternal plasma extraction
The buffy coat was collected from blood samples after
centrifugation at 1600 g for 10 min, whereas maternal plasma
was collected after an additional microcentrifugation at 16000 g
for 10 min. Buffy coat DNA was extracted using a standard
phenol-chloroform method. Four milliliters of maternal plasma
from each pregnancy were used for DNA extraction using the
QIAamp DNA blood Mini Kit (Qiagen, Crawley, UK) according
to the manufacturer’s instructions with minor modifica-
tions[19],[24]. In order to obtain efficient recovery of DNA
without decreasing its concentration, some slight modifications of
the elution protocols that were provided by the manufacturer were
made following the previous procedure [19]. The yield of cfDNA
from each maternal plasma sample could be increased when the
maternal plasma volume processed the 200-mL aliquots limitation
on manufacturers. In our procedure, 4 mL of each plasma from
pregnant women was extracted by use of five Qiagen minicolumns
by processing two 400-mL aliquots on each of them. The cfDNA
immobilized on the five columns was manually eluted one by one
with a total of 140 mL of autoclaved water and the isolated cfDNA
from one maternal plasma sample was in 70 mL final volumes.
The CVS samples and amniotic fluid samples were handled and
analyzed using the multiplex PCR-based mini-sequencing and the
a-thalassemia deletion Gap-PCR as previously described by Xiao
et al [25] in four clinical centers.
Diagnostic strategy
In a-thalassaemia with a cis double gene deletion, the presence of
the paternally inherited SNP allele in the maternal plasma would
suggest that fetus had inherited the paternal normal a-globin allele
and thus would not manifest hemoglobin Bart’s hydrops fetalis; the
diagnosticstrategyisproposedasshowninFigure1.TheNIPDflow
chart for exclusion of a large fetal deletion (the 22
SEA deletion)
from cfDNA in maternal plasma is illustrated in Figure 2. A total of
67 at-risk heterozygous couples with the (22
SEA) deletion were
recruited for this study. Initially, peripheral blood samples were
collected from each of the at-risk couples, white blood cells from all
couples were then used to isolate genomic DNA, and maternal
plasma was used to isolate cfDNA; subsequently, quantitative real-
time PCR (Q-PCR) was performed to quantify total cfDNA and
cffDNA in the maternal plasma. Secondly, multiplex PCR-based
mini-sequencing was used to identify informative markers using
genomic DNA from both parents by screening for nine previously
known SNPs within the deletion breakpoints. Finally, an allele-
specific real-time PCR method was used to detect the normal
paternally inherited fetal allele using cfDNA in maternal plasma,
according to the detailed information on one or more specific SNPs
(generally two sites were selected) that differ in the maternal and
paternal genomes. The NIPD results from analyses on all families
with informative SNPs were compared with results obtained from
conventional invasive prenatal diagnosis (CIPD) in a blinded
manner. The CIPD results were uncovered only once the genotypes
obtained by NIPD were scored.
Screening for informative SNPs within deletion
breakpoints
Genomic DNA from the 67 couples was used to select informative
markers useful for further non-invasive testing. Informative SNP
markers were identified by multiplex PCR amplification using a
Perkin Elmer Gene Amp PCR system 9600 thermal cycler (Applied
Biosystems,Fostercity,CA),followedbymini-sequencing basedona
fluorescent-labelled dideoxy single-base extension of an unlabeled
oligonucleotide primer or primers that hybridize upstream of the
SNP site. The analysis was performed using an ABI3730 Genetic
Analyzer and GeneMapper v3.7 software. The specific primer
sequences and PCR cycling conditions for the informative SNP
markers are listed in Table 1. For the multiplex PCR amplification,
50 ng of genomic DNA was used as the template. The final volume
was 20 mL, containing 10 pmol of primer mixture, 2 mL1 0 6PCR
buffer (Mg
2+ free, Invitrogen), 0.8 mL5 0m MM g C l 2 (Invitrogen),
0.5 mL 10 mM dNTPs (Takara), and 1 U Platimum Taq DNA
polymerase (Invitrogen). After an initial incubation at 95uCf o r
15 min, the reaction was cycled for 30 s at 94uC, 30 s at 56uC, and
1m i na t6 8 uC for 32 cycles, followed by a final extension for 30 min
at68uC.ExcessprimersanddNTPswereremovedbytheadditionof
5 U shrimp alkaline phosphatase (SAP) and 2 U Exol to 15 mLo f
PCR product and incubation of the mixture at 37uCf o r1h o u r ,
followed by 75uC for 15 min. Following the PCR reaction, 5 mLw a s
run as needed on a 1.5% agarose gel to check efficiency and
specificity. Sequence of the single base extension primers including
different polymeric T tails (Table 1). 2 mL of purified PCR product
from parental samples and 2 mL from the controls were used as the
template. The reaction was carried out in a final volume of 5 mL,
containing 2.5 mL of SNaPshot HMultiplex Ready Reaction Mix
NIPD of Homozygous a
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cycled for 10 s at 96uC, 5 s at 50uC, and 30 s at 60uCf o r2 5c y c l e s .
Excess nucleotides were removed by the addition of 1 mL( 1U / mL)
SAP and 1 U CIP, and incubation of the mixture at 37uCf o r1h
followed by 75uC for 15 min. Purified product from control DNA
was diluted 1:10 before being charged in the automated sequencer.
For the analysis, 0.5 mL of purified product from the parent’s
samples and 1 mL from the controls were mixed with 9 mLo fH i - D i
formamide and 0.5 mL of GeneScan 120 Liz size standard, followed
by incubation of the mixture at 95uCf o r5 m i na n dt h e n
immediately frozen 5 min.
Quantification of circulating DNA in the plasma
Real-time Q-PCR was performed using primers and probe
specific to the GAPDH gene in all pregnancies to determine the
total amount of circulatory maternal plasma DNA. The male-
specific SRY gene was used to monitor the presence of cffDNA and
quantify cffDNA. This was achieved according to a method
previously described by Birch et al [26]. The amount of circulatory
maternal plasma DNA obtained from 67 pregnant women and
cffDNA from mothers bearing male fetuses was calculated using
real-time PCR threshold cycle values.
Specificity and sensitivity of allele-specific real-time PCR
To define the sensitivity and specificity of allele-specific real-
time PCR for detection of fetal DNA in the maternal plasma for
this study, we conducted a series of experiments performed on
artificial mixtures of mutant allele diluted into wild-type allele
samples. For each SNP, 100 ng genomic DNA was successively
diluted at 1:1, 1:10, 1:100, 1:1000, and 1:10000 in water and used
as a starting template for amplification. In addition, DNA samples
that affect the ratio of paternal versus maternal alleles were
prepared in PCR reaction tubes by mixing 22
SEA/aa genomic
DNA with maternal allele spiked in varying dilutions of 1:1,1:2,
1:5, 1:10, 1:20, 1:50, 1:100, 1:500, 1:1000, 1:5000 and 1:10000 in
22
SEA/aa genomic DNA with paternal allele diluents. The
experiment was repeated twice. We optimized the specificity of
each of the allele-specific assays for informative SNPs by assessing
several factors including buffers composition, temperature, and
length of PCR amplification cycles, together with the use of
various oligonucletide primers [16], [19]. We then used the
DCT, (Paternal-Maternal) approach to measure the quantitative
differences between the paternal allele and maternal allele [16].
We also used melting curve analysis to monitor the presence of the
paternal allele.
Figure 1. Strategy for the non-invasive prenatal exclusion of homozygous (22
SEA) deletion in maternal plasma. Schematic drawing
showing the basic principle of our strategy for the non-invasive prenatal exclusion of homozygous (22
SEA) deletion based on SNP typing linked to
the paternal-normal a-globin allele. The normal a-globin gene cluster and corresponding deleted region of (22
SEA) allele are denoted by the colored
box with black line and the orange dotted line, respectively. The at-risk heterozygous couples sharing the same (22
SEA) deletion are shown on the
top and the possible consequences of NIPD for the fetus are demonstrated by the bottom panel of this figure. The arrows indicate an informative SNP
identified within the deletion breakpoints that can be used to differentiate between the mother’s (with T allele, downward arrows) and the father’s
(with C allele, upward arrows) normal allele. If C allele is not detected in the cffDNA fraction of maternal plasma, the fetus may either be
heterozygous, those who inherit a normal maternal T allele and a deleted paternal allele, or homozygous for the (22
SEA) allele, those who inherit
deleted alleles from both parents. In contrast, the presence of C allele in cffDNA denotes that the fetus inherits the normal paternal allele, and
therefore, we can exclude the possibility of Hb Bart’s syndrome for the fetus.
doi:10.1371/journal.pone.0024779.g001
NIPD of Homozygous a
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doi:10.1371/journal.pone.0024779.g002
Table 1. The oligonucleotide sequences of Multiplex PCR amplification and extension primer sequences for the mini-sequencing
reaction.
Marker
ID SNP ID
Marker position
on NG_000006.1
a Multiplex PCR Sequence (59to 39)
Amplicon
(bp) ASPE Primer Sequence (59to 39)
Product
length (bp)
1 rs2858935 g.26719G.C F-primer: CCTCCTGGCAGAGCAGTAACTT 255 (T)17-TCCACACAGACGGGAACCCG 38
R-primer: CCGCCCTGGCCTCCTTAT
2 rs75368786 g.27606C.A F-primer: CCGTGGTGCTGACCGAAAAA 315 (T)28-TGGCCTTGGTCTGTGCCTGT 49
R-primer: TGGTTGGAAGCCCGATTCA
3 rs2541675 g.29599A.G F-primer: AGGCACCTCCTGGCAACTT 362 (T)33-CGGTCTGGGAGAAAGTTGGC 54
R-primer: GGCCAAGTGAGAGGAAGGTC
4 rs2974771 g.31921T.C F-primer: CTACAACTACTGCCACAGGCTCT 136 (T)31-AAAATACCATCATACTGTAGATACC 57
R-primer: GAATGGCGCAGAGCTGAAT
5 rs2541669 g.33004C.T F-primer: GTCACAGTGAACCACGACCTCT 235 (T)38-ATGACTTGGGGCTTAGCCAG 59
R-primer: CTTTCCCTCTGGCGATAGTCA
6 rs2238369 g.35483T.C F-primer: GGAATCCATGCTGGGAAGTT 217 (T)23-GGTGGAGAGGACCCTGTCAC 44
R-primer: GTGGAGAGGGGAGGGAACT
7 rs11639532 g.36023G.A F-primer: ACGGGGGAAGCATTGCTAA 539 (T)26-GGGGAAGCATTGCTAAGCT 46
8 rs2858942 g.36517A.C R-primer: GGTGTGGACGAGGCATTCA9 (T)32-GCCCTCAGACTAACCCTGGTC 54
9 rs3760046 g.38757T.C F-primer: CGCTGGACCCTAGAGTGCTT 314 (T)38-AGAGGTCCTCCCACATATGGG 60
R-primer: CCGCACCCCTGATTTCATCT
aGenBank accession number.
Abbreviations: SNP, single nucleotide polymorphism; bp, base pair.
doi:10.1371/journal.pone.0024779.t001
NIPD of Homozygous a
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maternal plasma
Allele specific real-time PCR was performed to detect the
paternally inherited normal allele in the presence of an excess of the
corresponding maternal sequence. As all informative SNP artificial
experiments are functional, the analysis to detect paternally
inherited fetal allele by allele specific real-time PCR in the maternal
plasma was performed on a Thermocycler sequence detector
(Stratagene Mx3005; La Jolla, CA, USA). For AS-PCR analysis,
10 mL of DNA isolated from maternal plasma was used in the PCR.
Maternal plasma DNA was amplified in a final reaction volume of
25 mL containing 10 mM wild type primer or mutant primer
0.25 mL, 10 mM common primer 0.25 mL (Table S1), and 12.5 mL
SYBRH Green Real-time PCR Master Mix (Applied Biosystems,
Foster city, CA). The assay protocol started with an amplification
procedure consisting of a denaturation step of 30 sec at 95uC, 55
amplification cycles of 10 s at 95uC, 10 s at annealing temperature
for each SNP marker (Table S1), and 20 s at 72uC; and this
procedure was followed by a melting analysis procedure consisting
of a denaturation step of 1 min at 95uC, and a stepwise temperature
increase from 60uCt o9 5 uC at 0.5uC/step with 5 s detection for
each step. The fluorescence from SYBR channel was recorded at
each step during the annealing and the melting analysis procedure.
Statistical analysis
Statistical analyses were conducted using SPSS 14.0 (Lead
Technologies. Inc., Chicago, IL, USA). P,0.05 values were
considered statistically significant.
Results
Allele frequencies of 16 SNP markers obtained from 450
chromosomes in Southern Chinese are listed in Table 2. Nine SNPs
with minor allele frequency (MAF) .0.15 were considered to be
informative and were used in our protocol. Three SNP markers
(rs2514675, rs2974771 and rs2858942) were highly informative
(MAF.0.45). The locations of the nine SNPs are in the common
region between the 59 and 39 end breakpoints of three a-thalassaemia
double-gene deletions as shown in Figure S1 and Table S2.
The mean concentration of cfDNA obtained from maternal
plasma of 65 pregnancies was 611.63 genome-equivalents per
milliliter (GE/mL); the mean concentration of fetal DNA in 31
plasma samples from mothers bearing male fetuses was 47.35
GE/mL. The concentration of circulating DNA obtained from
maternal plasma of 65 pregnancies was within a certain range
87.8–1556 GE/mL (Table S3). On the basis of our experience
with AS-PCR, it is possible to detect certain types of genetic
alterations present at amount of 2 copies in a PCR tube (Panel A
in Figure 3). In practice, we used 50 genome-equivalents of cfDNA
as a lower cut-off value. The amount of input DNA (obtained from
4-mL maternal plasma samples) much exceeded 50 genome-
equivalents to permit accurate analysis. They would be sufficient
for the real-time AS-PCR assay to function reliably. In addition,
the majority of whole blood samples (97%) were processed directly
in four clinical centers and the plasma was sent frozen to our
center by commercial express courier service. Two samples (case
21 and 38) were sent as whole blood by commercial express
courier service. They were placed frozen gel packs directly on
tubes of blood, therefore resulted in hemolysis. Based on
previously reported results by Birch et al [26], these two cases
had to be excluded because the amount of cfDNA exceed 49940
genome equivalents/mL and was substantially higher than would
be expected in maternal samples during pregnancy (Table S3).
This method involved multiplex PCR-based mini-sequencing to
scan for informative SNPs followed by allele-specific real-time
PCR for NIPD results. The mini-sequencing assay demonstrated
Table 2. Allele frequencies of 16 SNP markers in 150 normal unrelated individuals and 150 heterozygote samples.
Marker ID SNP ID Marker position on NG_000006.1
a Number of markers with allele Allele frequency of
Major Minor Major Minor
b
Normal heterozygote Normal heterozygote
1 rs2858935 g.26719G.C 219 109 81 41 0.73 0.27
2 rs75368786 g.27606C.A 250 128 50 22 0.84 0.16
3 rs2541675 g.29599A.G 155 79 145 71 0.52 0.48
4 rs2974771 g.31921T.C 145 86 155 64 0.51 0.49
5 rs57397665 g.31990C.G
c 145 86 155 64 0.51 0.49
6 novel g.32905C.T 293 149 7 1 0.98 0.02
7 rs2541669 g.33004C.T 224 96 76 54 0.71 0.29
8 rs2362746 g.34247G.T 280 146 20 4 0.95 0.05
9 novel g.34951G.A 295 149 5 1 0.99 0.01
10 rs2238369 g.35483T.C 215 98 85 52 0.70 0.30
11 rs223830 g.35511G.A 278 146 22 4 0.94 0.06
12 rs11639532 g.36023G.A 242 118 58 32 0.80 0.20
13 novel g.36340G.A 296 150 4 0 0.99 0.01
14 rs2858942 g.36517A.C 164 84 136 66 0.55 0.45
15 rs3760046 g.38757T.C 252 130 46 20 0.85 0.15
16 rs1203834 g.42405C.T 260 145 40 5 0.90 0.10
aGenBank accession number.
bThose markers that minor allele frequency exceeded 0.15 were selected for informative markers.
cg.31990C.G was completely linked to the g.31921T.C, therefore we selected one of them for further analysis.
doi:10.1371/journal.pone.0024779.t002
NIPD of Homozygous a
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and exhibited suitability for high-throughput SNP scanning of
genomic DNA samples by multiple PCR-based fragment analysis.
We validated the assay using a group of previously sequenced
DNA samples (20 unrelated normal individuals and 20 22
SEA/
aa carriers). The SNP typing of each case was accurately defined
by the mini-sequencing assay at each nucleotide position analyzed,
exhibiting 100% concordance with the reference method. SNPs
were then assessed in 67 couples, and one or more different SNP(s)
within the deletion breakpoints between paternal and maternal
alleles was detected in 97% of the couples (65 cases). The SNPs
were informative and could be further used as candidate
polymorphic sites linked to the paternal-normal allele. Two cases
(family 15 and family 35) were non-discriminative as none of the
SNPs were informative (Table 3 and Table S5). Because the a-
globin genes are duplicate (a2 and a1) with a high degree of
homology (as illustrated in Figure S1), SNP ID rs2541669
(g.33004C.T) is located within the Z2 box of a2-globin gene,
which is homologous to the Z1 box of a1-globin gene; while SNP
ID rs2238369 (g.35483T.C) is located within the X1 box of a1-
globin gene, which is homologous to the X2 box of a2-globin
gene. The multiplex PCR of these two markers respectively yield
two amplicons with identical length. The mini-sequencing
amplicons of these two markers show the presence of two peaks
of amplification in heterozygous (22
SEA) samples whereas all
SNPs tested should be hemizygous. However, such expected
detection results do not influence our ability to correctly type SNPs
for each of these two sites. As illustrated in panel A of Figure S2-
family 7A, g.33004 T from father was detected by both T peak
(red) and additional C peak (black), thus indicating a truly positive
T allele in this case. The g.35483 T is similar to g.33004 T, with
two peaks showing in mother.
Figure 3. The sensitivity and specificity of allele-specific real-time PCR method used for NIPD. Panel A shows one set of representative
data from analysis of g.31921 T.C marker by allele-specific real-time PCR, in which the SNP profiling of artificial model samples is exported by
amplification blot (left) and dissociation curve analysis (right). Our results showed superior sensitivity and specificity in all dilutions (see materials and
methods), indicated by the arrows for each test, with a sensitivity of detection of 2 copies of the target sequence. Panel B shows the quantitative
difference between the respective CT values (DCT) of maternal alleles (CT, maternal) and paternal alleles (CT, paternal) in analysis of g.31921T.C artificial
model samples (see Materials and Methods). These results indicated a clear discrimination of the paternal allele from the maternal allele on
experimental serial dilutions. Following the DCT,(paternal-maternal) analysis, the maternal allele cluster is above a DCT value of 6, while the paternal allele
cluster is at a value of less than 6, thus the arbitrarily assigned DCT cut-off value (gray dotted line) was used to distinguish between the presence of
maternal from paternal alleles in the present study. Panel C shows the NIPD results obtained from detection of 65 at-risk fetus using 9 SNP markers in
cfDNA as paternal-normal marker by allele-specific real-time PCR. Among 65 samples tested, correct appraisal of the presence (n=33) or absence
(n=30) of the paternal-normal allele. Two cases labeled uncertain due to sample hemolysis by mishandling in the process of blood transport.
doi:10.1371/journal.pone.0024779.g003
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recombinant mutant clones were obtained in order to develop the
allele specific real-time PCR assay technology. Because a mixture of
maternal and paternal alleles was present, a model to test the
discrimination capability between paternal and maternal alleles was
established by subtracting the respective CT values (DCT) of maternal
alleles (CT, Maternal) and paternal alleles (CT, Paternal)u s i n gas e r i a lo f
artificial model samples for each of the 9 SNPs. These assessments
permitted establishment of tentative cut-off DCT value that could
serve to distinguish between samples in which the paternal inherited
allele was absent and thosesamples in which it was present. Following
the DCT, (Paternal-Maternal) analysis, the presence of paternally inherited
alleles was at a DCT value of less than 6 (Table S4). This method
permitted a clear discrimination between maternal and paternal
allele, even with experimental conditions whereby the maternal allele
was diluted in paternal allele of the order expected in maternal
plasmasamples(Figure3).Theresultsofthemodelallelespecificreal-
time PCR experiment demonstrated our optimized protocol could
detect one copy of paternal DNA in every50 copies of maternal DNA
(Table S4). As illustrated in figure 3A, the data from the analysis of the
g.31921T.C marker by the allele-specific real-time PCR assay
showed unequivocal results. This assessment permitted the establish-
ment of a tentative cut off value that could serve to discriminate
between the presence and absence of the paternal-normal allele in the
clinical cfDNA samples (Figure 3B). Furthermore, based on this cut
off value we were able to correctly determine the paternal-normal
allele of cffDNA from all 65 cases, revealing the sensitivity and robust
accuracy of this technique (Figure 3C).
As shown in Table 3, a total of 65 cases were examined for the
paternal-normal allele and the presence of those normal allele was
detected in 2 out of 5 cases for one discriminative SNP, 2 out of 6
cases for two discriminative SNPs, 3 out of 7 cases for three
discriminative SNPs, 1 out of 5 cases for four discriminative SNPs,
14 out of 25 cases for five discriminative SNPs, 11 out of 15 cases
for six discriminative SNPs, and 0 out of 2 cases for seven
discriminative SNPs. Two uncertain results were obtained in 2
cases in this study due to sample hemolysis. Homozygosity for the
(22
SEA) deletion was accurately ruled out in 33 out of 67 (49.3%,
95% CI 25.4–78.6%) pregnancies tested. The overall sensitivity for
the nine paternal SNP markers detected reached 100% and the
specificity was 93.8% (Table 3). NIPD of fetuses who were at-risk
for a-thalassemia major in two families using our protocol are
illustrated in Figure S2. Results for the paternal-normal allele in
the maternal plasma from 63 families obtained from analyses in
which our protocol was implemented were in concordance with
results obtained by conventional prenatal diagnosis (Table S5).
Discussion
In the present blind study of 67 high genetic risk couples we
have shown that PCR-based DNA detection of paternal SNPs
within the deletion breakpoints is a rapid and reliable technique
for non-invasive prenatal diagnosis of deletional a-thalassemia. A
group of informative SNP markers within the (22
SEA) break-
points that differ in the maternal and paternal chromosomes
dependent on the natural variation in the Chinese population
studied have been identified. Furthermore, the SNP markers
designed in the present strategy are available for exclusion of the
paternal deleted chromosome of other two common deletion of
22
THAI and 22
FIL resulting in a-thalassemia in Southeast Asia
[23] (Figure S1), thereby potentially extended to include testing for
these deletions for NIPD applications. We demonstrated the
feasibility of our newly developed method as 97% of the couples
(65 cases) had one or more different SNP(s) within the breakpoints
of deletions between paternal and maternal alleles. 2 of the 67
cases were non-informative, due to the inheritance of identical
SNP markers in both parents. Therefore, it is possible to exclude
nearly 50% (33/67) of the at-risk subjects tested by exclusion of
the homozygous (22
SEA) deletion based on detection of the
paternally inherited fetal normal allele. With a potential
application in one-half of pregnancies our SNP-based assay thus
generally overcomes the limitations of microsatellite markers,
although our assay cannot be used to differentiate homozygous
deletions from carriers in the remaining 50% of at-risk
pregnancies. In some cases, it is possible to detect fetal genetic
loci for disease-causing point mutations, as well as SNPs linked to
paternally inherited fetal mutant alleles involved in disorders such
as b-thalassemia [15]–[18],[21],[27], achondroplasia [28], and
myotonic dystrophy [29], although this is highly technically
challenging. However, there are very few NIPD applications that
can analyze single-gene disorders caused by large deletions
through a reliable approach using cffDNA in maternal plasma.
This novel approach has been successfully applied to the detection
of a-thalassemia in the present study, and could be expanded to
other autosomal genetic diseases due to gene deletions, such as
22q11.2 deletion syndrome and deletional b-thalassemia.
Table 3. Summary of the results of the informative SNP alleles by the analysis of cell free fetal DNA in the maternal plasma.
Number of informative polymorphisms No. of cases Correct detection of cases/Total No. of cases Sensitivity (%) Specificity (%)
Presence of paternal allele Absence of paternal allele
02 U I
a UI
a --
1 5 2/2 3/3 100 100
2 6 2/2 4/4 100 100
3 7 3/3 4/4 100 100
4 5 1/1 4/4 100 100
5 25 14/14 9/11
b 100 81.8
6 15 11/11 4/4 100 100
7 2 0 2/2 100 100
Total (excluding uninformative cases) 65 33/33 30/32 100 93.8
aTwo families are excluded due to lack of informative SNP markers. UI: uninformative.
bTwo cases are classified as uncertain, due to mishandling the samples.
doi:10.1371/journal.pone.0024779.t003
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element of the molecular test involved in our approach is the two-
step protocol involving multiplex PCR-based mini-sequencing
and allele specific real-time PCR. By the use of the former
method, we have shown that it is possible to simultaneously detect
nine SNPs within breakpoints of the deletion tested using
genomic DNA from high-risk parental individuals. The results
obtained from our random samples indicated that two to seven
informative SNPs could be detected 89.55% of at-risk couples.
Thereby, the test is easy to process since only one SNP is needed
in the practical protocol of NIPD for detection of the paternally
inherited fetal allele in maternal plasma. The latter is used to
detect one informative SNP selected from the above several sites
for direct exportation of cfDNA sample NIPD results. Another
informative SNP sites can be used to provide double-check
information on NIPD for the same plasma sample previously
tested if it is necessary. Uncertain results were obtained in 2 cases
in this study due to sample hemolysis that could lead to
significantly increasing maternal DNA in the tested samples;
thereby the amount of maternal DNA in the PCR sample can
interfere with the assay. There were several factors observed to
affect the sensitivity and reproducibility of the assay system,
particularly PCR polymerase, hence AmpliTaq Gold LD
polymerase (Applied biosystem, No. 4367659) was selected to
guarantee consistent results and we were able to consistently
detect 2 copies of paternal alleles without interference from the
maternal sequences in the model PCR experiment (Figure 3A).
In our study, plasma samples were collected during 8.5–25
weeks of gestation (mean 19.12 weeks), representing a relatively
high level of cffDNA, in which the paternally inherited fetal SNPs,
masked by the background of maternal DNA, can be definitely
detected through allele-specific real-time PCR, indicating that the
sensitivity of the molecular test is able to meet the demands of
NIPD for clinical samples. Due to the limited quantities of cffDNA
isolated between 8 and 12 weeks of gestation in early pregnancy
we believe that it will be important to further enhance detection of
SNPs in the application of this technology. Our method could be
improved for non-invasive exclusion of fetal large deletions in
monogenic disorders by inclusion of an additional step of selective
enrichment of cell-free fetal DNA in maternal plasma by size
fractionation [30]. Moreover, we would enhance the accuracy of
our non-invasive prenatal exclusion of homozygous a-thalassaemia
by using SNPs that lie outside the (22
SEA) deletion breakpoints as
controls in early pregnancy.
In conclusion, this is the first large scale study reporting a
contribution of detecting paternally inherited normal alleles within
deletion breakpoints from a
0-thalassemia patient maternal plasma
samples. Based on our results, which made use of a combination of
multiplex-PCR based mini-sequencing and allele-specific real-time
PCR, our strategy could be directly applicable for noninvasive
prenatal prediction of homozygous a-thalassaemia by maternal
plasma DNA analysis. The advantage of detecting these paternal
SNPs within deletion breakpoints in deletional Mendelian
disorders is that their presence could be used to exclude
pregnancies at risk for these disorders, thereby obviating the need
for an invasive prenatal diagnostic procedure. Furthermore, a
decrease of these risk-associated procedures could be achieved for
diagnosis of these common regional genetic disorders.
Supporting Information
Figure S1 Nine informative SNP markers are located
within the breakpoints of 22
THAI, 22
FIL and 22
SEA.
The detailed locations of nine SNP markers are listed in Table S1
that accompanies the online version of this article. The a-globin
genes are embedded within two highly homologous 4 kb
duplication units. These regions are divided into homologous
subsegments (X, Y, and Z) by non-homologous elements.
(TIF)
Figure S2 Representative NIPD for a-thalassemia in
two families performed using our protocol. The relevant
results of the multiplex PCR-based mini-sequencing chromato-
grams are shown in the two windows (mother in top, father in
middle and fetus in bottom), which were obtained from screening
for nine informative SNPs within the deletion breakpoints by
single-step test, with the arrows indicating those SNPs that differ in
the maternal and paternal genomes. Each of nine SNP markers
were detected in the given position of amplicons in different size
(the scale in base pair on horizontal axis), from left to right, they
are g.26719C.G, g.27606C.A, g.29599A.G, g.31921T.C,
g.33004C.T, g.35483T.C, g.36023G.A, g.36517A.C and
g.38757T.C. Each fluorescent dye corresponds to a different
nucleotide where blue represents G, green represents A, black
represents C, and red represents T. The CVS and amniotic fluid
samples were analyzed using the multiplex PCR-based mini-
sequencing by four clinical centers. The NIPD results for two at-
risk fetus using two informative SNPs by allele-specific real-time
PCR are shown in panel B (the specific SNPs tested are indicated
on the top of figure). The allele-specific SNP profiling of DNA
samples are exported by amplification blot (left) or dissociation
curve analysis (right), in which the corresponding arrows indicate
each profiling of samples amplified from four different sources,
with the corresponding specific bases marked in bracket,
FDP=fetal DNA in plasma; MDP=maternal DNA in plasma;
PDB=paternal DNA in blood; MDB=maternal DNA in blood;
NAP=nonspecific amplification products from primer-dimers;
NTC=no template control. As shown in family 7 of the figure, for
g.29599A.G marker, CT, Maternal=31.52, CT, Paternal=35.41,
DCT,(paternal-maternal)=3.84; for g.36517A.C marker, CT, Maternal=
30.96, CT, Paternal=34.86, DCT,(paternal-maternal)=3.90. The cffDNA
wasidentified ashavinginheritedpaternal-normalalleles(g.29599G
allele and g.36517C allele) in this family, and therefore, the NIPD
results above indicated an exclusion of homozygosity for a
0-
thalassemia in this fetus. However, in family 47 of the figure, for
g.26719C.G marker, CT, Maternal=34.53, CT, Paternal=43.97,
DCT, (paternal-maternal)=9.44; for g.31921T.C marker, CT, Maternal
=34.94, CT, Paternal=44.41, DCT, (paternal-maternal)=9.47. The
inherited paternal-normal alleles, g.26719G and g.31921C, was
not found in the cffDNA in plasma from Family 47, thus indicating
the possibility of heterozygous or homozygous for the (22
SEA)
deletion for this fetus. The comparative CIPD results for two
families using gap-PCR are shown in panel C. The gel
electrophoresis of PCR amplified fragments from normal allele
(1052 bp) and the (22
SEA) allele (740 bp). MA=100 bp DNA
Marker ladder (Takara), C=no DNA control, F=fetus (DNA from
CVS or amniocentesis), P=paternal, M=maternal, S=standard
control with wild-type, heterozygote and homozygote of the
(22
SEA) deletion, from right to left. Genotypes of these two fetuses
were confirmatively diagnosed as having aa/aa in Family 7
(1052 bp) and 22
SEA/22
SEA in Family 47 (740 bp).
(PDF)
Table S1 Oligonucleotide sequences for Allele-Specific
Real-time PCR.
(DOC)
Table S2 The location of nine SNP markers within
(22
SEA) deletion breakpoint regions.
(DOC)
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DNA by Real-time Quantitative-PCR.
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Table S4 Allele specific real-time PCR analysis of nine
SNP markers using a serial of artificial model samples.
(DOC)
Table S5 Comparison between the analysis of circulat-
ing fetal DNA and invasive procedure (CVS or amnio-
centesis).
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